Published in Oncotarget on November 25, 2016
The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol (2010) 7.58
p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev (2000) 2.74
Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev (2010) 2.32
Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol (2000) 2.17
Type I and II endometrial cancers: have they different risk factors? J Clin Oncol (2013) 2.01
p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene (2011) 1.86
The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol (2001) 1.73
Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene (2005) 1.61
The tumor suppressor protein p16INK4a. Exp Cell Res (1997) 1.57
Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010. J Gynecol Oncol (2013) 1.56
Prediction of cancer incidence and mortality in Korea, 2014. Cancer Res Treat (2014) 1.55
Contemporary management of endometrial cancer. Lancet (2012) 1.51
Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat (2001) 1.46
Human colorectal cancers with an intact p16/cyclin D1/pRb pathway have up-regulated p16 expression and decreased proliferation in small invasive tumor clusters. Am J Pathol (2000) 1.33
Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res (2005) 1.22
Co-expression of p16(INK4A) and laminin 5 gamma2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol (2003) 1.20
Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. Am J Pathol (2011) 1.12
Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res (2003) 1.02
The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum Pathol (2007) 1.00
Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer. Oncotarget (2015) 0.96
Cancer regression by senescence. N Engl J Med (2007) 0.93
Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies. Pathology (2008) 0.93
Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol (2005) 0.89
Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res (1999) 0.89
Endometrial cancer: Not your grandmother's cancer. Cancer (2016) 0.89
Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res (2008) 0.87
Current status of molecular biomarkers in endometrial cancer. Curr Oncol Rep (2014) 0.87
Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence. World J Gastroenterol (2006) 0.87
Overexpression of cytokeratin 17 is associated with the development of papillary thyroid carcinoma and the presence of lymph node metastasis. Int J Clin Exp Pathol (2015) 0.81
The role of pRB, p16 and cyclin D1 in colonic carcinogenesis. Hepatogastroenterology (2010) 0.81
Stromal p16 expression differentiates endometrial polyp from endometrial hyperplasia. Virchows Arch (2012) 0.80
Stromal p16 expression is significantly increased in malignant ovarian neoplasms. Oncotarget (2016) 0.79
Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer. Oncotarget (2015) 0.96
Stromal p16 expression is significantly increased in malignant ovarian neoplasms. Oncotarget (2016) 0.79
Hypergravity upregulates renal inducible nitric oxide synthase expression and nitric oxide production. Oncotarget (2016) 0.79
Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma. Oncotarget (2016) 0.78
High-grade squamous intraepithelial lesion arising adjacent to vulvar lymphangioma circumscriptum: a tertiary institutional experience. Oncotarget (2016) 0.78
Distinctive expression patterns of hypoxia-inducible factor-1α and endothelial nitric oxide synthase following hypergravity exposure. Oncotarget (2016) 0.78
Clinical outcomes of primary surgical treatment for acquired vulvar lymphangioma circumscriptum. Arch Gynecol Obstet (2015) 0.78
Clinicopathological and immunohistochemical characterization of papillary proliferation of the endometrium: A single institutional experience. Oncotarget (2016) 0.77
Cytomorphological characteristics of glassy cell carcinoma of the uterine cervix: histopathological correlation and human papillomavirus genotyping. Oncotarget (2016) 0.77
Clinical outcomes of advanced-stage glassy cell carcinoma of the uterine cervix: a need for reappraisal. Oncotarget (2016) 0.75
Downregulation of osteoprotegerin expression in metastatic colorectal carcinoma predicts recurrent metastasis and poor prognosis. Oncotarget (2016) 0.75
Gastric acid response to acute exposure to hypergravity. Oncotarget (2016) 0.75
Adrenalectomy abolishes hypergravity-induced gastric acid hyposecretion. Oncotarget (2017) 0.75
Simulated weightlessness affects the expression and activity of neuronal nitric oxide synthase in the rat brain. Oncotarget (2017) 0.75
Increased Brahma-related Gene 1 Expression Predicts Distant Metastasis and Shorter Survival in Patients with Invasive Ductal Carcinoma of the Breast. Anticancer Res (2016) 0.75
Clinicopathological Characteristics of Mitotically-active Cellular Fibroma of the Ovary: A Single-institutional Experience. Anticancer Res (2017) 0.75
B-cell translocation gene 1 is downregulated by promoter methylation in ovarian carcinoma. J Cancer (2017) 0.75
Impact of lymphovascular invasion on lymph node metastasis for patients undergoing radical prostatectomy with negative resection margin. BMC Cancer (2017) 0.75